Study:
Diagnostic and Prognostic Value of Serial PCT Measurements in Critically Ill Patients
Rationale:
n/a
Purpose:
In 2005, the Food and Drug Administration (FDA) approved procalcitonin in conjunction with
other laboratory markers to aid in the risk assessment of critically ill patients with
severe infection (sepsis). Although considerable literature exists regarding the usefulness
of Procalcitonin (PCT) as a marker of sepsis, there are still potential uses for PCT
measurements that are not yet explored and its value among the critically ill patients
remains unclear. This study seeks to better understand the usefulness of measuring PCT
values in patients admitted to the Medical ICU for a variety of reasons and in particular
with severe infection (sepsis).
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Sepsis |
n/a |
N/A |
Verified by
The Cleveland Clinic
February, 2013
Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT01362920
Study Type: Interventional
Study Design: Observational Model: Case Control, Time Perspective: Prospective
Cleveland Clinic
Cleveland, Ohio 44195
United States
Jorge A Guzman, MD., Principal Investigator